Author

Jewel Johanns 1

1 4Janssen Research & Development, LLC

Efficacy of Ustekinumab Subcutaneous Maintenance Treatment by Induction-Dose Subgroup in the UNIFI Study of Patients with Ulcerative Colitis

Silvio Danese, Bruce E. Sands, William Sandborn, Colleen W. Marano, Christopher D. O'Brien, Hongyan Zhang, Jewel Johanns, Laurent Peyrin-Biroulet, Ellen Scherl, Tadakazu Hisamatsu, Remo Panaccione

ENDOSCOPIC AND CLINICAL PREDICTORS OF 1-YEAR OUTCOME IN CHILDREN WITH ULCERATIVE COLITIS TREATED WITH INFLIXIMAB: RESULTS FROM THE T72 TRIAL

Dan Turner, Gigi Veerman, Lakshmi Damaraju, Marion Blank, Jeffrey S Hyams, Anne Griffiths, Jewel Johanns

EXPOSURE-RESPONSE TO SC USTEKINUMAB IN MODERATE –SEVERE CROHN’S DISEASE: RESULTS FROM THE IM-UNITI MAINTENANCE STUDY

Omoniyi J. Adedokun, Zhenhua Xu, Christopher Gasink, Douglas Jacobstein, Philippe Szapary, Jewel Johanns, Long-Long Gao, Hugh M Davis, Steve Hanauer, Brian G. Feagan, Subrata Ghosh, William Sandborn

FECAL LACTOFERRIN AND CALPROTECTIN AS SURROGATE MARKERS OF MUCOSAL HEALING: POST-HOC ANALYSIS FROM THE PURSUIT SC INDUCTION STUDY

Walter Reinisch, William Sandborn, Brian G. Feagan, Paul Rutgeerts, Peter R. Gibson, Judy Collins, Dino Tarabar, Zbigniew Hebzda, Jean-Frederic Colombel, Colleen W. Marano, Richard S Strauss, Jewel Johanns, Hongyan Zhang

Impact of Response and Inflammatory Burden at Start of Maintenance Therapy on Clinical Efficacy of Ustekinumab Dosing Regimen in UC: Week 44 Results from UNIFI

Remo Panaccione, Laurent Peyrin-Biroulet, Silvio Danese, Colleen W. Marano, Christopher D. O'Brien, Philippe Szapary, Hongyan Zhang, Jewel Johanns, Rupert W Leong, Ramesh P. Arasaradnam, David Rowbotham, Maria T. Abreu, Bruce E. Sands

INDUCTION COMBINATION THERAPY WITH GUSELKUMAB AND GOLIMUMAB FOLLOWED BY GUSELKUMAB MONOTHERAPY MAINTENANCE: RESULTS OF THE PHASE 2A, RANDOMIZED, DOUBLE-BLIND, PROOF-OF-CONCEPT VEGA STUDY

Julian Panés, Bruce E. Sands, William J. Sandborn, Matthew Germinaro, Marion Vetter, Shihong Sheng, Jewel Johanns, Brian G. Feagan

PATIENT-REPORTED OUTCOMES OF RESPONSE AND REMISSION FOLLOWING GUSELKUMAB INDUCTION TREATMENT AS MEASURED BY THE INFLAMMATORY BOWEL DISEASE QUESTIONNAIRE: RESULTS THROUGH WEEK 12 OF THE PHASE 2 GALAXI 1 STUDY

Remo Panaccione, Geert R. D'Haens, Kathleen Weisel, Susana Gonzalez, Mary Elleen Frustaci, Zijiang Yang, Jewel Johanns, Matthew Germinaro, Bruce E. Sands, David T. Rubin, Chenglong Han, Julian Panés, Silvio Danese

Pharmacokinetics and Exposure-Response Relationships of Ustekinumab in Patients with Ulcerative Colitis: Results from the UNIFI Induction and Maintenance Studies

Joseph Adedokun, Zhenhua Xu, Colleen W. Marano, Christopher O’Brien, Philippe Szapary, Hongyan Zhang, Jewel Johanns, Rupert W Leong, Tadakazu Hisamatsu, Gert Van Assche, Silvio Danese, Maria T. Abreu, Bruce E. Sands, William Sandborn

SAFETY AND EFFICACY OF USTEKINUMAB INDUCTION THERAPY IN PATIENTS WITH MODERATE TO SEVERE ULCERATIVE COLITIS: RESULTS FROM THE PHASE 3 UNIFI STUDY

Bruce E. Sands, William Sandborn, Remo Panaccione, Christopher D. O'Brien, Hongyan Zhang, Jewel Johanns, Laurent Peyrin-Biroulet, Gert Van Assche, Silvio Danese, Stephan Targan, Maria T. Abreu, Tadakazu Hisamatsu, Philippe Szapary, Colleen W. Marano

THE EFFICACY AND SAFETY OF GUSELKUMAB INDUCTION THERAPY IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE CROHN'S DISEASE: WEEK 12 INTERIM ANALYSES FROM THE PHASE 2 GALAXI 1 STUDY

William Sandborn, Daphne Chan, Jewel Johanns, Grace Lang, Omoniyi J. Adedokun, Anita Afzali, Jane Andrews, Geert R. D'Haens, Silvio Danese, Tadakazu Hisamatsu, Remo Panaccione, Julian Panés, Walter Reinisch, David T. Rubin, Bruce E. Sands, Brian G. Feagan

Item 11 - 20 / 24
1
2
3